1
|
Tang Q, Pollard LW, Homa KE, Kovar DR, Trybus KM. Acetylation of fission yeast tropomyosin does not promote differential association with cognate formins. Cytoskeleton (Hoboken) 2023; 80:77-92. [PMID: 36692369 PMCID: PMC10121778 DOI: 10.1002/cm.21745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 01/02/2023] [Accepted: 01/17/2023] [Indexed: 01/25/2023]
Abstract
It was proposed from cellular studies that S. pombe tropomyosin Cdc8 (Tpm) segregates into two populations due to the presence or absence of an amino-terminal acetylation that specifies which formin-mediated F-actin networks it binds, but with no supporting biochemistry. To address this mechanism in vitro, we developed methods for S. pombe actin expression in Sf9 cells. We then employed 3-color TIRF microscopy using all recombinant S. pombe proteins to probe in vitro multicomponent mechanisms involving actin, acetylated and unacetylated Tpm, formins, and myosins. Acetyl-Tpm exhibits tight binding to actin in contrast to weaker binding by unacetylated Tpm. In disagreement with the differential recruitment model, Tpm showed no preferential binding to filaments assembled by the FH1-FH2-domains of two S. pombe formins, nor did Tpm binding have any bias towards the growing formin-bound actin filament barbed end. Although our in vitro findings do not support a direct formin-tropomyosin interaction, it is possible that formins bias differential tropomyosin isoform recruitment through undiscovered mechanisms. Importantly, despite a 12% sequence divergence between skeletal and S. pombe actin, S. pombe myosins Myo2 and Myo51 exhibited similar motile behavior with these two actins, validating key prior findings with these myosins that used skeletal actin.
Collapse
Affiliation(s)
- Qing Tang
- Department of Molecular Physiology and Biophysics, University of Vermont, Burlington VT
| | - Luther W. Pollard
- Department of Molecular Physiology and Biophysics, University of Vermont, Burlington VT
| | - Kaitlin E. Homa
- Molecular Genetics and Cell Biology, Biochemistry and Molecular Biology, the University of Chicago, Chicago, IL
| | - David R. Kovar
- Molecular Genetics and Cell Biology, Biochemistry and Molecular Biology, the University of Chicago, Chicago, IL
| | - Kathleen M. Trybus
- Department of Molecular Physiology and Biophysics, University of Vermont, Burlington VT
| |
Collapse
|
2
|
Rasicci DV, Tiwari P, Bodt SML, Desetty R, Sadler FR, Sivaramakrishnan S, Craig R, Yengo CM. Dilated cardiomyopathy mutation E525K in human beta-cardiac myosin stabilizes the interacting-heads motif and super-relaxed state of myosin. eLife 2022; 11:e77415. [PMID: 36422472 PMCID: PMC9691020 DOI: 10.7554/elife.77415] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 11/08/2022] [Indexed: 11/25/2022] Open
Abstract
The auto-inhibited, super-relaxed (SRX) state of cardiac myosin is thought to be crucial for regulating contraction, relaxation, and energy conservation in the heart. We used single ATP turnover experiments to demonstrate that a dilated cardiomyopathy (DCM) mutation (E525K) in human beta-cardiac myosin increases the fraction of myosin heads in the SRX state (with slow ATP turnover), especially in physiological ionic strength conditions. We also utilized FRET between a C-terminal GFP tag on the myosin tail and Cy3ATP bound to the active site of the motor domain to estimate the fraction of heads in the closed, interacting-heads motif (IHM); we found a strong correlation between the IHM and SRX state. Negative stain electron microscopy and 2D class averaging of the construct demonstrated that the E525K mutation increased the fraction of molecules adopting the IHM. Overall, our results demonstrate that the E525K DCM mutation may reduce muscle force and power by stabilizing the auto-inhibited SRX state. Our studies also provide direct evidence for a correlation between the SRX biochemical state and the IHM structural state in cardiac muscle myosin. Furthermore, the E525 residue may be implicated in crucial electrostatic interactions that modulate this conserved, auto-inhibited conformation of myosin.
Collapse
Affiliation(s)
- David V Rasicci
- Department of Cellular and Molecular Physiology, Penn State College of MedicineHersheyUnited States
| | - Prince Tiwari
- Department of Radiology, Division of Cell Biology and Imaging, UMass Chan Medical SchoolWorcesterUnited States
| | - Skylar ML Bodt
- Department of Cellular and Molecular Physiology, Penn State College of MedicineHersheyUnited States
| | - Rohini Desetty
- Department of Cellular and Molecular Physiology, Penn State College of MedicineHersheyUnited States
| | - Fredrik R Sadler
- Department of Genetics, Cell Biology, and Development, University of Minnesota Twin CitiesMinneapolisUnited States
| | - Sivaraj Sivaramakrishnan
- Department of Genetics, Cell Biology, and Development, University of Minnesota Twin CitiesMinneapolisUnited States
| | - Roger Craig
- Department of Radiology, Division of Cell Biology and Imaging, UMass Chan Medical SchoolWorcesterUnited States
| | - Christopher M Yengo
- Department of Cellular and Molecular Physiology, Penn State College of MedicineHersheyUnited States
| |
Collapse
|
3
|
Soppina P, Patel N, Shewale DJ, Rai A, Sivaramakrishnan S, Naik PK, Soppina V. Kinesin-3 motors are fine-tuned at the molecular level to endow distinct mechanical outputs. BMC Biol 2022; 20:177. [PMID: 35948971 PMCID: PMC9364601 DOI: 10.1186/s12915-022-01370-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Accepted: 07/06/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Kinesin-3 family motors drive diverse cellular processes and have significant clinical importance. The ATPase cycle is integral to the processive motility of kinesin motors to drive long-distance intracellular transport. Our previous work has demonstrated that kinesin-3 motors are fast and superprocessive with high microtubule affinity. However, chemomechanics of these motors remain poorly understood. RESULTS We purified kinesin-3 motors using the Sf9-baculovirus expression system and demonstrated that their motility properties are on par with the motors expressed in mammalian cells. Using biochemical analysis, we show for the first time that kinesin-3 motors exhibited high ATP turnover rates, which is 1.3- to threefold higher compared to the well-studied kinesin-1 motor. Remarkably, these ATPase rates correlate to their stepping rate, suggesting a tight coupling between chemical and mechanical cycles. Intriguingly, kinesin-3 velocities (KIF1A > KIF13A > KIF13B > KIF16B) show an inverse correlation with their microtubule-binding affinities (KIF1A < KIF13A < KIF13B < KIF16B). We demonstrate that this differential microtubule-binding affinity is largely contributed by the positively charged residues in loop8 of the kinesin-3 motor domain. Furthermore, microtubule gliding and cellular expression studies displayed significant microtubule bending that is influenced by the positively charged insert in the motor domain, K-loop, a hallmark of kinesin-3 family. CONCLUSIONS Together, we propose that a fine balance between the rate of ATP hydrolysis and microtubule affinity endows kinesin-3 motors with distinct mechanical outputs. The K-loop, a positively charged insert in the loop12 of the kinesin-3 motor domain promotes microtubule bending, an interesting phenomenon often observed in cells, which requires further investigation to understand its cellular and physiological significance.
Collapse
Affiliation(s)
- Pushpanjali Soppina
- Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, 382355, India.,Department of Biotechnology and Bioinformatics, Sambalpur University, Sambalpur, Orissa, 768019, India
| | - Nishaben Patel
- Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, 382355, India.,Department of Genetics, Cell Biology and Development, University of Minnesota, Minnesota, MN, 55455, USA
| | - Dipeshwari J Shewale
- Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, 382355, India
| | - Ashim Rai
- Department of Genetics, Cell Biology and Development, University of Minnesota, Minnesota, MN, 55455, USA
| | - Sivaraj Sivaramakrishnan
- Department of Genetics, Cell Biology and Development, University of Minnesota, Minnesota, MN, 55455, USA
| | - Pradeep K Naik
- Department of Biotechnology and Bioinformatics, Sambalpur University, Sambalpur, Orissa, 768019, India
| | - Virupakshi Soppina
- Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, 382355, India.
| |
Collapse
|
4
|
Hou L, Kumar M, Anand P, Chen Y, El-Bizri N, Pickens CJ, Seganish WM, Sadayappan S, Swaminath G. Modulation of myosin by cardiac myosin binding protein-C peptides improves cardiac contractility in ex-vivo experimental heart failure models. Sci Rep 2022; 12:4337. [PMID: 35288601 PMCID: PMC8921245 DOI: 10.1038/s41598-022-08169-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 03/03/2022] [Indexed: 01/23/2023] Open
Abstract
Cardiac myosin binding protein-C (cMyBP-C) is an important regulator of sarcomeric function. Reduced phosphorylation of cMyBP-C has been linked to compromised contractility in heart failure patients. Here, we used previously published cMyBP-C peptides 302A and 302S, surrogates of the regulatory phosphorylation site serine 302, as a tool to determine the effects of modulating the dephosphorylation state of cMyBP-C on cardiac contraction and relaxation in experimental heart failure (HF) models in vitro. Both peptides increased the contractility of papillary muscle fibers isolated from a mouse model expressing cMyBP-C phospho-ablation (cMyBP-CAAA) constitutively. Peptide 302A, in particular, could also improve the force redevelopment rate (ktr) in papillary muscle fibers from cMyBP-CAAA (nonphosphorylated alanines) mice. Consistent with the above findings, both peptides increased ATPase rates in myofibrils isolated from rats with myocardial infarction (MI), but not from sham rats. Furthermore, in the cMyBP-CAAA mouse model, both peptides improved ATPase hydrolysis rates. These changes were not observed in non-transgenic (NTG) mice or sham rats, indicating the specific effects of these peptides in regulating the dephosphorylation state of cMyBP-C under the pathological conditions of HF. Taken together, these studies demonstrate that modulation of cMyBP-C dephosphorylation state can be a therapeutic approach to improve myosin function, sarcomere contractility and relaxation after an adverse cardiac event. Therefore, targeting cMyBP-C could potentially improve overall cardiac performance as a complement to standard-care drugs in HF patients.
Collapse
Affiliation(s)
- Luqia Hou
- Cardiometabolic Department, Merck & Co., Inc., 213 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Mohit Kumar
- Division of Cardiovascular Health and Disease, Department of Internal Medicine, Heart, Lung and Vascular Institute, University of Cincinnati, Cincinnati, OH, 45267, USA
| | - Priti Anand
- Cardiometabolic Department, Merck & Co., Inc., 213 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Yinhong Chen
- Cardiometabolic Department, Merck & Co., Inc., 213 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Nesrine El-Bizri
- Cardiometabolic Department, Merck & Co., Inc., 213 East Grand Ave., South San Francisco, CA, 94080, USA
| | - Chad J Pickens
- Analytical R&D, Merck & Co., Inc., South San Francisco, CA, 94080, USA
| | - W Michael Seganish
- Discovery Chemistry, Merck & Co., Inc., South San Francisco, CA, 94080, USA
| | - Sakthivel Sadayappan
- Division of Cardiovascular Health and Disease, Department of Internal Medicine, Heart, Lung and Vascular Institute, University of Cincinnati, Cincinnati, OH, 45267, USA
| | - Gayathri Swaminath
- Cardiometabolic Department, Merck & Co., Inc., 213 East Grand Ave., South San Francisco, CA, 94080, USA.
| |
Collapse
|
5
|
Gyimesi M, Rauscher AÁ, Suthar SK, Hamow KÁ, Oravecz K, Lőrincz I, Borhegyi Z, Déri MT, Kiss ÁF, Monostory K, Szabó PT, Nag S, Tomasic I, Krans J, Tierney PJ, Kovács M, Kornya L, Málnási-Csizmadia A. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2. J Pharmacol Exp Ther 2021; 376:358-373. [PMID: 33468641 DOI: 10.1124/jpet.120.000167] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 10/07/2020] [Indexed: 11/22/2022] Open
Abstract
Blebbistatin, para-nitroblebbistatin (NBleb), and para-aminoblebbistatin (AmBleb) are highly useful tool compounds as they selectively inhibit the ATPase activity of myosin-2 family proteins. Despite the medical importance of the myosin-2 family as drug targets, chemical optimization has not yet provided a promising lead for drug development because previous structure-activity-relationship studies were limited to a single myosin-2 isoform. Here we evaluated the potential of blebbistatin scaffold for drug development and found that D-ring substitutions can fine-tune isoform specificity, absorption-distribution-metabolism-excretion, and toxicological properties. We defined the inhibitory properties of NBleb and AmBleb on seven different myosin-2 isoforms, which revealed an unexpected potential for isoform specific inhibition. We also found that NBleb metabolizes six times slower than blebbistatin and AmBleb in rats, whereas AmBleb metabolizes two times slower than blebbistatin and NBleb in human, and that AmBleb accumulates in muscle tissues. Moreover, mutagenicity was also greatly reduced in case of AmBleb. These results demonstrate that small substitutions have beneficial functional and pharmacological consequences, which highlight the potential of the blebbistatin scaffold for drug development targeting myosin-2 family proteins and delineate a route for defining the chemical properties of further derivatives to be developed. SIGNIFICANCE STATEMENT: Small substitutions on the blebbistatin scaffold have beneficial functional and pharmacological consequences, highlighting their potential in drug development targeting myosin-2 family proteins.
Collapse
Affiliation(s)
- Máté Gyimesi
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Anna Á Rauscher
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Sharad Kumar Suthar
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Kamirán Á Hamow
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Kinga Oravecz
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - István Lőrincz
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Zsolt Borhegyi
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Máté T Déri
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Ádám F Kiss
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Katalin Monostory
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Pál Tamás Szabó
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Suman Nag
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Ivan Tomasic
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Jacob Krans
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Patrick J Tierney
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - Mihály Kovács
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - László Kornya
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| | - András Málnási-Csizmadia
- Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.)
| |
Collapse
|
6
|
Gyimesi M, Horváth ÁI, Túrós D, Suthar SK, Pénzes M, Kurdi C, Canon L, Kikuti C, Ruppel KM, Trivedi DV, Spudich JA, Lőrincz I, Rauscher AÁ, Kovács M, Pál E, Komoly S, Houdusse A, Málnási-Csizmadia A. Single Residue Variation in Skeletal Muscle Myosin Enables Direct and Selective Drug Targeting for Spasticity and Muscle Stiffness. Cell 2020; 183:335-346.e13. [PMID: 33035452 DOI: 10.1016/j.cell.2020.08.050] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 07/24/2020] [Accepted: 08/27/2020] [Indexed: 12/14/2022]
Abstract
Muscle spasticity after nervous system injuries and painful low back spasm affect more than 10% of global population. Current medications are of limited efficacy and cause neurological and cardiovascular side effects because they target upstream regulators of muscle contraction. Direct myosin inhibition could provide optimal muscle relaxation; however, targeting skeletal myosin is particularly challenging because of its similarity to the cardiac isoform. We identified a key residue difference between these myosin isoforms, located in the communication center of the functional regions, which allowed us to design a selective inhibitor, MPH-220. Mutagenic analysis and the atomic structure of MPH-220-bound skeletal muscle myosin confirmed the mechanism of specificity. Targeting skeletal muscle myosin by MPH-220 enabled muscle relaxation, in human and model systems, without cardiovascular side effects and improved spastic gait disorders after brain injury in a disease model. MPH-220 provides a potential nervous-system-independent option to treat spasticity and muscle stiffness.
Collapse
Affiliation(s)
- Máté Gyimesi
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary; Motorpharma, Ltd., Szilágyi Erzsébet fasor 27, 1026 Budapest, Hungary.
| | - Ádám I Horváth
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary
| | - Demeter Túrós
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary
| | - Sharad Kumar Suthar
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary; Printnet, Ltd., Kisgömb utca 25-27, 1135 Budapest, Hungary
| | - Máté Pénzes
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary
| | - Csilla Kurdi
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary
| | - Louise Canon
- Structural Motility, Institut Curie, Paris Université Sciences et Lettres, Sorbonne Université, CNRS UMR144, 75005 Paris, France
| | - Carlos Kikuti
- Structural Motility, Institut Curie, Paris Université Sciences et Lettres, Sorbonne Université, CNRS UMR144, 75005 Paris, France
| | - Kathleen M Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Beckman Center B400, 279 W. Campus Drive, Stanford, CA 94305, USA
| | - Darshan V Trivedi
- Department of Biochemistry, Stanford University School of Medicine, Beckman Center B400, 279 W. Campus Drive, Stanford, CA 94305, USA
| | - James A Spudich
- Department of Biochemistry, Stanford University School of Medicine, Beckman Center B400, 279 W. Campus Drive, Stanford, CA 94305, USA
| | - István Lőrincz
- Printnet, Ltd., Kisgömb utca 25-27, 1135 Budapest, Hungary
| | - Anna Á Rauscher
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary; Motorpharma, Ltd., Szilágyi Erzsébet fasor 27, 1026 Budapest, Hungary
| | - Mihály Kovács
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary; Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary and Brunszvik u. 2, 2462 Martonvásár, Hungary
| | - Endre Pál
- Department of Neurology, University of Pécs, Rét utca 2, 7623 Pécs, Hungary
| | - Sámuel Komoly
- Department of Neurology, University of Pécs, Rét utca 2, 7623 Pécs, Hungary
| | - Anne Houdusse
- Structural Motility, Institut Curie, Paris Université Sciences et Lettres, Sorbonne Université, CNRS UMR144, 75005 Paris, France
| | - András Málnási-Csizmadia
- MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary; Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary and Brunszvik u. 2, 2462 Martonvásár, Hungary.
| |
Collapse
|
7
|
Pénzes M, Túrós D, Máthé D, Szigeti K, Hegedűs N, Rauscher AÁ, Tóth P, Ivic I, Padmanabhan P, Pál G, Dobolyi Á, Gyimesi M, Málnási-Csizmadia A. Direct myosin-2 inhibition enhances cerebral perfusion resulting in functional improvement after ischemic stroke. Theranostics 2020; 10:5341-5356. [PMID: 32373216 PMCID: PMC7196296 DOI: 10.7150/thno.42077] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Accepted: 02/03/2020] [Indexed: 12/29/2022] Open
Abstract
Acute ischemic stroke treatment faces an unresolved obstacle as capillary reperfusion remains insufficient after thrombolysis and thrombectomy causing neuronal damage and poor prognosis. Hypoxia-induced capillary constriction is mediated by actomyosin contraction in precapillary smooth muscle cells (SMCs) therefore smooth muscle myosin-2 could be an ideal target with potentially high impact on reperfusion of capillaries. Methods: The myosin-2 inhibitor para-aminoblebbistatin (AmBleb) was tested on isolated human and rat arterioles to assess the effect of AmBleb on vasodilatation. Transient middle cerebral artery occlusion (MCAO) was performed on 38 male Wistar rats followed by local administration of AmBleb into the ischemic brain area. Development of brain edema and changes in cerebrovascular blood flow were assessed using MRI and SPECT. We also tested the neurological deficit scores and locomotor asymmetry of the animals for 3 weeks after the MCAO operation. Results: Our results demonstrate that AmBleb could achieve full relaxation of isolated cerebral arterioles. In living animals AmBleb recovered cerebral blood flow in 32 out of the 65 affected functional brain areas in MCAO operated rats, whereas only 8 out of the 67 affected areas were recovered in the control animals. Animals treated with AmBleb also showed significantly improved general and focal deficit scores in neurological functional tests and showed significantly ameliorated locomotor asymmetry. Conclusion: Direct inhibition of smooth muscle myosin by AmBleb in pre-capillary SMCs significantly contribute to the improvement of cerebral blood reperfusion and brain functions suggesting that smooth muscle myosin inhibition may have promising potential in stroke therapies as a follow-up treatment of physical or chemical removal of the occluding thrombus.
Collapse
|
8
|
Teng GZ, Shaikh Z, Liu H, Dawson JF. M-class hypertrophic cardiomyopathy cardiac actin mutations increase calcium sensitivity of regulated thin filaments. Biochem Biophys Res Commun 2019; 519:148-152. [PMID: 31481237 DOI: 10.1016/j.bbrc.2019.08.151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 08/27/2019] [Indexed: 12/22/2022]
Abstract
Hypertrophic cardiomyopathy is a commonly occurring cardiovascular disease resulting primarily from changes in proteins participating in muscle contraction in the heart, including the cardiac actin protein. Changes in cardiac actin located exclusively in the myosin binding site are called M-class variants and include the H88Y, R95C, and E99K substitutions and F90Δ deletion. The prevailing hypothesis for these mutations is that hypertrophic cardiomyopathy is the result of increased calcium sensitivity of contraction in the myocardium. To test this hypothesis, we studied the activity of myosin at varying calcium concentrations in the presence of regulated thin filaments containing M-class cardiac actin variants. We found that all M-class cardiac actin variants exhibit increased calcium sensitivity, with the R95C variant also displaying significant decreases in maximal myosin activity. This work represents the first characterization of all M-class variant proteins and suggests that drugs targeting contraction specifically to treat hypertrophic cardiomyopathy must consider the impact on both calcium sensitivity and maximal myosin activity on overall heart health.
Collapse
Affiliation(s)
- Grace Zi Teng
- Department of Molecular & Cellular Biology and Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON, N1G 2W1, Canada
| | - Zeeshan Shaikh
- Department of Molecular & Cellular Biology and Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON, N1G 2W1, Canada
| | - Haidun Liu
- Department of Molecular & Cellular Biology and Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON, N1G 2W1, Canada
| | - John F Dawson
- Department of Molecular & Cellular Biology and Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON, N1G 2W1, Canada.
| |
Collapse
|
9
|
Vera CD, Johnson CA, Walklate J, Adhikari A, Svicevic M, Mijailovich SM, Combs AC, Langer SJ, Ruppel KM, Spudich JA, Geeves MA, Leinwand LA. Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties. J Biol Chem 2019; 294:17451-17462. [PMID: 31582565 DOI: 10.1074/jbc.ra119.010563] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 09/18/2019] [Indexed: 02/01/2023] Open
Abstract
Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterized by left ventricular hypertrophy and cardiac hyper-contractility. Mutations in the β-cardiac myosin heavy chain gene (β-MyHC) are a major cause of HCM, but the specific mechanistic changes to myosin function that lead to this disease remain incompletely understood. Predicting the severity of any β-MyHC mutation is hindered by a lack of detailed examinations at the molecular level. Moreover, because HCM can take ≥20 years to develop, the severity of the mutations must be somewhat subtle. We hypothesized that mutations that result in early onset disease would have more severe changes in function than do later onset mutations. Here, we performed steady-state and transient kinetic analyses of myosins carrying one of seven missense mutations in the motor domain. Of these seven, four were previously identified in early onset cardiomyopathy screens. We used the parameters derived from these analyses to model the ATP-driven cross-bridge cycle. Contrary to our hypothesis, the results indicated no clear differences between early and late onset HCM mutations. Despite the lack of distinction between early and late onset HCM, the predicted occupancy of the force-holding actin·myosin·ADP complex at [Actin] = 3 K app along with the closely related duty ratio (the fraction of myosin in strongly attached force-holding states), and the measured ATPases all changed in parallel (in both sign and degree of change) compared with wildtype (WT) values. Six of the seven HCM mutations were clearly distinct from a set of previously characterized DCM mutations.
Collapse
Affiliation(s)
- Carlos D Vera
- BioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309
| | - Chloe A Johnson
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Jonathan Walklate
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Arjun Adhikari
- Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305
| | | | | | - Ariana C Combs
- BioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309
| | - Stephen J Langer
- BioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309
| | - Kathleen M Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305
| | - James A Spudich
- Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305
| | - Michael A Geeves
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
| | - Leslie A Leinwand
- BioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, Colorado 80309
| |
Collapse
|
10
|
Sidhu N, Dawson JF. A crosslinked and ribosylated actin trimer does not interact productively with myosin. Biochem Cell Biol 2019; 97:140-147. [DOI: 10.1139/bcb-2018-0082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
A purified F-actin-derived actin trimer that interacts with end-binding proteins did not activate or bind the side-binding protein myosin under rigor conditions. Remodeling of the actin trimer by the binding of gelsolin did not rescue myosin binding, nor did the use of different means of inhibiting the polymerization of the trimer. Our results demonstrate that ADP-ribosylation on all actin subunits of an F-actin-derived trimer inhibits myosin binding and that the binding of DNase-I to the pointed end subunits of a crosslinked trimer also remodels the myosin binding site. Taken together, this work highlights the need for a careful balance between modification of actin subunits and maintaining protein–protein interactions to produce a physiologically relevant short F-actin complex.
Collapse
Affiliation(s)
- Navneet Sidhu
- Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada
- Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada
| | - John F. Dawson
- Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada
- Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada
| |
Collapse
|
11
|
Wilkinson AW, Diep J, Dai S, Liu S, Ooi YS, Song D, Li TM, Horton JR, Zhang X, Liu C, Trivedi DV, Ruppel KM, Vilches-Moure JG, Casey KM, Mak J, Cowan T, Elias JE, Nagamine CM, Spudich JA, Cheng X, Carette JE, Gozani O. SETD3 is an actin histidine methyltransferase that prevents primary dystocia. Nature 2018; 565:372-376. [PMID: 30626964 PMCID: PMC6511263 DOI: 10.1038/s41586-018-0821-8] [Citation(s) in RCA: 96] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2018] [Accepted: 11/30/2018] [Indexed: 01/17/2023]
Abstract
For over fifty years, the methylation of mammalian actin at histidine 73
(actin-H73me) has been known to exist1. Beyond mammals, we find that actin-H73me is conserved
in several additional model animal and plant organisms. Despite the
pervasiveness of H73me, its function is enigmatic, and the enzyme generating
this modification is unknown. Here, we identify SETD3 (SET
domain protein 3) as the physiologic
actin histidine 73 methyltransferase. Structural studies reveal that an
extensive network of interactions clamps the actin peptide on the SETD3 surface
to properly orient H73 within the catalytic pocket and facilitate methyl
transfer. H73me reduces the nucleotide exchange rate on actin monomers and
modestly accelerates actin filament assembly. Mice lacking SETD3 show complete
loss of actin-H73me in multiple tissues and quantitative proteomics singles out
actin-H73 as the principal physiologic SETD3 substrate. SETD3 deficient female
mice have severely decreased litter sizes due to primary maternal dystocia that
is refractory to ecbolic induction agents. Further, depletion of SETD3 impairs
signal-induced contraction in primary human uterine smooth muscle cells.
Together, our results identify the first mammalian protein histidine
methyltransferase and uncover a pivotal role for SETD3 and actin-H73me in the
regulation of smooth muscle contractility. Our data also support the broader
hypothesis where protein histidine methylation acts as a common regulatory
mechanism.
Collapse
Affiliation(s)
| | - Jonathan Diep
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA
| | - Shaobo Dai
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Shuo Liu
- Department of Biology, Stanford University, Stanford, CA, USA
| | - Yaw Shin Ooi
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA
| | - Dan Song
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - Tie-Mei Li
- Department of Biology, Stanford University, Stanford, CA, USA
| | - John R Horton
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Xing Zhang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chao Liu
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - Darshan V Trivedi
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - Katherine M Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - José G Vilches-Moure
- Department of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Kerriann M Casey
- Department of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | | | - Tina Cowan
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Joshua E Elias
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA
| | - Claude M Nagamine
- Department of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - James A Spudich
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - Xiaodong Cheng
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Jan E Carette
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
| | - Or Gozani
- Department of Biology, Stanford University, Stanford, CA, USA.
| |
Collapse
|
12
|
Ujfalusi Z, Vera CD, Mijailovich SM, Svicevic M, Yu EC, Kawana M, Ruppel KM, Spudich JA, Geeves MA, Leinwand LA. Dilated cardiomyopathy myosin mutants have reduced force-generating capacity. J Biol Chem 2018; 293:9017-9029. [PMID: 29666183 PMCID: PMC5995530 DOI: 10.1074/jbc.ra118.001938] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 04/14/2018] [Indexed: 11/06/2022] Open
Abstract
Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) can cause arrhythmias, heart failure, and cardiac death. Here, we functionally characterized the motor domains of five DCM-causing mutations in human β-cardiac myosin. Kinetic analyses of the individual events in the ATPase cycle revealed that each mutation alters different steps in this cycle. For example, different mutations gave enhanced or reduced rate constants of ATP binding, ATP hydrolysis, or ADP release or exhibited altered ATP, ADP, or actin affinity. Local effects dominated, no common pattern accounted for the similar mutant phenotype, and there was no distinct set of changes that distinguished DCM mutations from previously analyzed HCM myosin mutations. That said, using our data to model the complete ATPase contraction cycle revealed additional critical insights. Four of the DCM mutations lowered the duty ratio (the ATPase cycle portion when myosin strongly binds actin) because of reduced occupancy of the force-holding A·M·D complex in the steady state. Under load, the A·M·D state is predicted to increase owing to a reduced rate constant for ADP release, and this effect was blunted for all five DCM mutations. We observed the opposite effects for two HCM mutations, namely R403Q and R453C. Moreover, the analysis predicted more economical use of ATP by the DCM mutants than by WT and the HCM mutants. Our findings indicate that DCM mutants have a deficit in force generation and force-holding capacity due to the reduced occupancy of the force-holding state.
Collapse
Affiliation(s)
- Zoltan Ujfalusi
- From the School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
- the Department of Biophysics, University of Pécs, Medical School, Szigeti Street 12, H-7624 Pécs, Hungary
| | - Carlos D Vera
- the BioFrontiers Institute and Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado 80309
| | | | - Marina Svicevic
- the Faculty of Science, University of Kragujevac, Kragujevac 34000, Serbia
| | | | - Masataka Kawana
- Biochemistry, Stanford University School of Medicine, Stanford, California 94305, and
| | - Kathleen M Ruppel
- Biochemistry, Stanford University School of Medicine, Stanford, California 94305, and
| | - James A Spudich
- Biochemistry, Stanford University School of Medicine, Stanford, California 94305, and
| | - Michael A Geeves
- From the School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom,
| | - Leslie A Leinwand
- the BioFrontiers Institute and Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado 80309,
| |
Collapse
|
13
|
Liu C, Kawana M, Song D, Ruppel KM, Spudich JA. Controlling load-dependent kinetics of β-cardiac myosin at the single-molecule level. Nat Struct Mol Biol 2018; 25:505-514. [PMID: 29867217 PMCID: PMC6092189 DOI: 10.1038/s41594-018-0069-x] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 04/26/2018] [Indexed: 01/29/2023]
Abstract
Concepts in molecular tension sensing in biology are growing and have their origins in studies of muscle contraction. In the heart muscle, a key parameter of contractility is the detachment rate of myosin from actin, which determines the time that myosin is bound to actin in a force-producing state and, importantly, depends on the load (force) against which myosin works. Here we measure the detachment rate of single molecules of human β-cardiac myosin and its load dependence. We find that both can be modulated by both small-molecule compounds and cardiomyopathy-causing mutations. Furthermore, effects of mutations can be reversed by introducing appropriate compounds. Our results suggest that activating versus inhibitory perturbations of cardiac myosin are discriminated by the aggregate result on duty ratio, average force, and ultimately average power output and suggest that cardiac contractility can be controlled by tuning the load-dependent kinetics of single myosin molecules.
Collapse
Affiliation(s)
- Chao Liu
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
| | - Masataka Kawana
- Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Dan Song
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
| | - Kathleen M Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA
- Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA, USA
| | - James A Spudich
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
| |
Collapse
|
14
|
Banerjee C, Hu Z, Huang Z, Warrington JA, Taylor DW, Trybus KM, Lowey S, Taylor KA. The structure of the actin-smooth muscle myosin motor domain complex in the rigor state. J Struct Biol 2017; 200:325-333. [PMID: 29038012 DOI: 10.1016/j.jsb.2017.10.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 10/11/2017] [Accepted: 10/12/2017] [Indexed: 01/08/2023]
Abstract
Myosin-based motility utilizes catalysis of ATP to drive the relative sliding of F-actin and myosin. The earliest detailed model based on cryo-electron microscopy (cryoEM) and X-ray crystallography postulated that higher actin affinity and lever arm movement were coupled to closure of a feature of the myosin head dubbed the actin-binding cleft. Several studies since then using crystallography of myosin-V and cryoEM structures of F-actin bound myosin-I, -II and -V have provided details of this model. The smooth muscle myosin II interaction with F-actin may differ from those for striated and non-muscle myosin II due in part to different lengths of important surface loops. Here we report a ∼6 Å resolution reconstruction of F-actin decorated with the nucleotide-free recombinant smooth muscle myosin-II motor domain (MD) from images recorded using a direct electron detector. Resolution is highest for F-actin and the actin-myosin interface (3.5-4 Å) and lowest (∼6-7 Å) for those parts of the MD at the highest radius. Atomic models built into the F-actin density are quite comparable to those previously reported for rabbit muscle actin and show density from the bound ADP. The atomic model of the MD, is quite similar to a recently published structure of vertebrate non-muscle myosin II bound to F-actin and a crystal structure of nucleotide free myosin-V. Larger differences are observed when compared to the cryoEM structure of F-actin decorated with rabbit skeletal muscle myosin subfragment 1. The differences suggest less closure of the 50 kDa domain in the actin bound skeletal muscle myosin structure.
Collapse
Affiliation(s)
- Chaity Banerjee
- Department of Computer Science, Florida State University, Tallahassee, FL 32306-4530, United States
| | - Zhongjun Hu
- Institute of Molecular Biophysics, Kasha Laboratory, Florida State University, Tallahassee, FL 32306-4380, United States
| | - Zhong Huang
- Institute of Molecular Biophysics, Kasha Laboratory, Florida State University, Tallahassee, FL 32306-4380, United States
| | - J Anthony Warrington
- Institute of Molecular Biophysics, Kasha Laboratory, Florida State University, Tallahassee, FL 32306-4380, United States
| | - Dianne W Taylor
- Institute of Molecular Biophysics, Kasha Laboratory, Florida State University, Tallahassee, FL 32306-4380, United States
| | - Kathleen M Trybus
- Health Science Research Facility 130, 149 Beaumont Avenue, Department of Molecular Physiology & Biophysics, University of Vermont, Burlington, VT 05405, United States
| | - Susan Lowey
- Health Science Research Facility 130, 149 Beaumont Avenue, Department of Molecular Physiology & Biophysics, University of Vermont, Burlington, VT 05405, United States
| | - Kenneth A Taylor
- Institute of Molecular Biophysics, Kasha Laboratory, Florida State University, Tallahassee, FL 32306-4380, United States.
| |
Collapse
|
15
|
Bookwalter CS, Tay CL, McCrorie R, Previs MJ, Lu H, Krementsova EB, Fagnant PM, Baum J, Trybus KM. Reconstitution of the core of the malaria parasite glideosome with recombinant Plasmodium class XIV myosin A and Plasmodium actin. J Biol Chem 2017; 292:19290-19303. [PMID: 28978649 PMCID: PMC5702669 DOI: 10.1074/jbc.m117.813972] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 09/27/2017] [Indexed: 11/08/2022] Open
Abstract
Motility of the apicomplexan malaria parasite Plasmodium falciparum is enabled by a multiprotein glideosome complex, whose core is the class XIV myosin motor, PfMyoA, and a divergent Plasmodium actin (PfAct1). Parasite motility is necessary for host-cell invasion and virulence, but studying its molecular basis has been hampered by unavailability of sufficient amounts of PfMyoA. Here, we expressed milligram quantities of functional full-length PfMyoA with the baculovirus/Sf9 cell expression system, which required a UCS (UNC-45/CRO1/She4p) family myosin chaperone from Plasmodium spp. In addition to the known light chain myosin tail interacting protein (MTIP), we identified an essential light chain (PfELC) that co-purified with PfMyoA isolated from parasite lysates. The speed at which PfMyoA moved actin was fastest with both light chains bound, consistent with the light chain–binding domain acting as a lever arm to amplify nucleotide-dependent motions in the motor domain. Surprisingly, PfELC binding to the heavy chain required that MTIP also be bound to the heavy chain, unlike MTIP that bound the heavy chain independently of PfELC. Neither the presence of calcium nor deletion of the MTIP N-terminal extension changed the speed of actin movement. Of note, PfMyoA moved filaments formed from Sf9 cell–expressed PfAct1 at the same speed as skeletal muscle actin. Duty ratio estimates suggested that as few as nine motors can power actin movement at maximal speed, a feature that may be necessitated by the dynamic nature of Plasmodium actin filaments in the parasite. In summary, we have reconstituted the essential core of the glideosome, enabling drug targeting of both of its core components to inhibit parasite invasion.
Collapse
Affiliation(s)
- Carol S Bookwalter
- From the Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and
| | - Chwen L Tay
- the Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ, United Kingdom
| | - Rama McCrorie
- the Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ, United Kingdom
| | - Michael J Previs
- From the Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and
| | - Hailong Lu
- From the Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and
| | - Elena B Krementsova
- From the Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and
| | - Patricia M Fagnant
- From the Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and
| | - Jake Baum
- the Department of Life Sciences, Imperial College London, South Kensington, London SW7 2AZ, United Kingdom
| | - Kathleen M Trybus
- From the Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405 and
| |
Collapse
|
16
|
Liu H, Henein M, Anillo M, Dawson JF. Cardiac actin changes in the actomyosin interface have different effects on myosin duty ratio. Biochem Cell Biol 2017; 96:26-31. [PMID: 28972856 DOI: 10.1139/bcb-2017-0136] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease (CD) that commonly causes an increased size of cardiomyocytes in the left ventricle. The proteins myosin and actin interact in the myocardium to produce contraction through the actomyosin ATPase cycle. The duty ratio (r) of myosin is the proportion of the actomyosin ATPase cycle that myosin is bound to actin and does work. A common hypothesis is that HCM mutations increase contraction in cardiac sarcomeres; however, the available data are not clear on this connection. Based on previous work with human α-cardiac actin (ACTC), we hypothesize that HCM-linked ACTC variants with alterations near the myosin binding site have an increased r, producing more force. Myosin duty ratios using human ACTC variant proteins were calculated with myosin ATPase activity and in-vitro motility data. We found no consistent changes in the duty ratio of the ACTC variants, suggesting that other factors are involved in the development of HCM when ACTC variants are present.
Collapse
Affiliation(s)
- Haidun Liu
- Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada.,Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada
| | - Mary Henein
- Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada.,Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada
| | - Maria Anillo
- Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada.,Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada
| | - John F Dawson
- Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada.,Department of Molecular and Cellular Biology and the Centre for Cardiovascular Investigations, University of Guelph, Guelph, ON N1G 2W1, Canada
| |
Collapse
|
17
|
Molecular mechanisms and structural features of cardiomyopathy-causing troponin T mutants in the tropomyosin overlap region. Proc Natl Acad Sci U S A 2017; 114:11115-11120. [PMID: 28973951 DOI: 10.1073/pnas.1710354114] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Point mutations in genes encoding sarcomeric proteins are the leading cause of inherited primary cardiomyopathies. Among them are mutations in the TNNT2 gene that encodes cardiac troponin T (TnT). These mutations are clustered in the tropomyosin (Tm) binding region of TnT, TNT1 (residues 80-180). To understand the mechanistic changes caused by pathogenic mutations in the TNT1 region, six hypertrophic cardiomyopathy (HCM) and two dilated cardiomyopathy (DCM) mutants were studied by biochemical approaches. Binding assays in the absence and presence of actin revealed changes in the affinity of some, but not all, TnT mutants for Tm relative to WT TnT. HCM mutants were hypersensitive and DCM mutants were hyposensitive to Ca2+ in regulated actomyosin ATPase activities. To gain better insight into the disease mechanism, we modeled the structure of TNT1 and its interactions with Tm. The stability predictions made by the model correlated well with the affinity changes observed in vitro of TnT mutants for Tm. The changes in Ca2+ sensitivity showed a strong correlation with the changes in binding affinity. We suggest the primary reason by which these TNNT2 mutations between residues 92 and 144 cause cardiomyopathy is by changing the affinity of TnT for Tm within the TNT1 region.
Collapse
|
18
|
Fission yeast myosin Myo2 is down-regulated in actin affinity by light chain phosphorylation. Proc Natl Acad Sci U S A 2017; 114:E7236-E7244. [PMID: 28808035 DOI: 10.1073/pnas.1703161114] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Studies in fission yeast Schizosaccharomyces pombe have provided the basis for the most advanced models of the dynamics of the cytokinetic contractile ring. Myo2, a class-II myosin, is the major source of tension in the contractile ring, but how Myo2 is anchored and regulated to produce force is poorly understood. To enable more detailed biochemical/biophysical studies, Myo2 was expressed in the baculovirus/Sf9 insect cell system with its two native light chains, Rlc1 and Cdc4. Milligram yields of soluble, unphosphorylated Myo2 were obtained that exhibited high actin-activated ATPase activity and in vitro actin filament motility. The fission yeast specific chaperone Rng3 was thus not required for expression or activity. In contrast to nonmuscle myosins from animal cells that require phosphorylation of the regulatory light chain for activation, phosphorylation of Rlc1 markedly reduced the affinity of Myo2 for actin. Another unusual feature of Myo2 was that, unlike class-II myosins, which generally form bipolar filamentous structures, Myo2 showed no inclination to self-assemble at approximately physiological salt concentrations, as analyzed by sedimentation velocity ultracentrifugation. This lack of assembly supports the hypothesis that clusters of Myo2 depend on interactions at the cell cortex in structural units called nodes for force production during cytokinesis.
Collapse
|
19
|
The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat Struct Mol Biol 2017; 24:525-533. [PMID: 28481356 DOI: 10.1038/nsmb.3408] [Citation(s) in RCA: 146] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Accepted: 04/05/2017] [Indexed: 12/12/2022]
Abstract
Hypertrophic cardiomyopathy (HCM) is primarily caused by mutations in β-cardiac myosin and myosin-binding protein-C (MyBP-C). Changes in the contractile parameters of myosin measured so far do not explain the clinical hypercontractility caused by such mutations. We propose that hypercontractility is due to an increase in the number of myosin heads (S1) that are accessible for force production. In support of this hypothesis, we demonstrate myosin tail (S2)-dependent functional regulation of actin-activated human β-cardiac myosin ATPase. In addition, we show that both S2 and MyBP-C bind to S1 and that phosphorylation of either S1 or MyBP-C weakens these interactions. Importantly, the S1-S2 interaction is also weakened by four myosin HCM-causing mutations but not by two other mutations. To explain these experimental results, we propose a working structural model involving multiple interactions, including those with myosin's own S2 and MyBP-C, that hold myosin in a sequestered state.
Collapse
|
20
|
Kawana M, Sarkar SS, Sutton S, Ruppel KM, Spudich JA. Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy. SCIENCE ADVANCES 2017; 3:e1601959. [PMID: 28246639 PMCID: PMC5302870 DOI: 10.1126/sciadv.1601959] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 01/09/2017] [Indexed: 05/20/2023]
Abstract
Hypertrophic cardiomyopathy (HCM) affects 1 in 500 individuals and is an important cause of arrhythmias and heart failure. Clinically, HCM is characterized as causing hypercontractility, and therapies are aimed toward controlling the hyperactive physiology. Mutations in the β-cardiac myosin comprise ~40% of genetic mutations associated with HCM, and the converter domain of myosin is a hotspot for HCM-causing mutations; however, the underlying primary effects of these mutations on myosin's biomechanical function remain elusive. We hypothesize that these mutations affect the biomechanical properties of myosin, such as increasing its intrinsic force and/or its duty ratio and therefore the ensemble force of the sarcomere. Using recombinant human β-cardiac myosin, we characterize the molecular effects of three severe HCM-causing converter domain mutations: R719W, R723G, and G741R. Contrary to our hypothesis, the intrinsic forces of R719W and R723G mutant myosins are decreased compared to wild type and unchanged for G741R. Actin and regulated thin filament gliding velocities are ~15% faster for R719W and R723G myosins, whereas there is no change in velocity for G741R. Adenosine triphosphatase activities and the load-dependent velocity change profiles of all three mutant proteins are very similar to those of wild type. These results indicate that the net biomechanical properties of human β-cardiac myosin carrying these converter domain mutations are very similar to those of wild type or are even slightly hypocontractile, leading us to consider an alternative mechanism for the clinically observed hypercontractility. Future work includes how these mutations affect protein interactions within the sarcomere that increase the availability of myosin heads participating in force production.
Collapse
Affiliation(s)
- Masataka Kawana
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Saswata S. Sarkar
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Shirley Sutton
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Kathleen M. Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA 94305, USA
- Corresponding author. (J.A.S.); (K.M.R.)
| | - James A. Spudich
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
- Corresponding author. (J.A.S.); (K.M.R.)
| |
Collapse
|
21
|
Swenson AM, Tang W, Blair CA, Fetrow CM, Unrath WC, Previs MJ, Campbell KS, Yengo CM. Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle. J Biol Chem 2017; 292:3768-3778. [PMID: 28082673 DOI: 10.1074/jbc.m116.748780] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2016] [Revised: 01/05/2017] [Indexed: 01/10/2023] Open
Abstract
The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human β-cardiac myosin subfragment 1 (M2β-S1) containing a C-terminal Avi tag. We demonstrate that the maximum actin-activated ATPase activity of M2β-S1 is slowed more than 4-fold in the presence of OM, whereas the actin concentration required for half-maximal ATPase was reduced dramatically (30-fold). We find OM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence of OM. The dominant pathway results in a slow transition between actomyosin·ADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads. OM causes an increase in duty ratio examined in the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (ktr) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose that OM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.
Collapse
Affiliation(s)
- Anja M Swenson
- From the Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
| | - Wanjian Tang
- From the Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
| | - Cheavar A Blair
- the Department of Physiology and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536-0298, and
| | - Christopher M Fetrow
- From the Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
| | - William C Unrath
- From the Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
| | - Michael J Previs
- the Department of Molecular Physiology and Biophysics, Cardiovascular Research Institute, University of Vermont, Burlington, Vermont 05405
| | - Kenneth S Campbell
- the Department of Physiology and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536-0298, and
| | - Christopher M Yengo
- From the Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033,
| |
Collapse
|
22
|
Chitano P, Wang L, Tin GYY, Ikebe M, Paré PD, Seow CY. Smooth muscle function and myosin polymerization. J Cell Sci 2017; 130:2468-2480. [DOI: 10.1242/jcs.202812] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 06/01/2017] [Indexed: 01/28/2023] Open
Abstract
Smooth muscle is able to function over a much broader length range than striated muscle. The ability to maintain contractility after a large length change is thought to be due to an adaptive process involving restructuring of the contractile apparatus to maximize overlap between the contractile filaments. The molecular mechanism for the length-adaptive behavior is largely unknown. In smooth muscle adapted to different lengths we quantified myosin monomers, basal and activation-induced myosin light chain (MLC) phosphorylation, shortening-velocity, power-output and active force. The muscle was able to generate a constant maximal force over a 2-fold length range when it was allowed to go through isometric contraction/relaxation cycles after each length change (length adaptation). In the relaxed state myosin monomer concentration and basal MLC phosphorylation decreased linearly, while in the activated state activation-induced MLC phosphorylation and shortening-velocity/power-output increased linearly with muscle length. The results suggest that recruitment of myosin monomers and oligomers into the actin filament lattice (where they form force-generating filaments) occurs during muscle adaptation to longer length with the opposite occurring during adaptation to shorter length.
Collapse
Affiliation(s)
- Pasquale Chitano
- Centre for Heart Lung Innovation - St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
| | - Lu Wang
- Respiratory Division, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Centre for Heart Lung Innovation - St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
| | - Gabrielle Y. Y. Tin
- Centre for Heart Lung Innovation - St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
| | - Mitsuo Ikebe
- Department of Cellular and Molecular Biology, University of Texas Health Science Center, Tyler, Texas, USA
| | - Peter D. Paré
- Respiratory Division, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Centre for Heart Lung Innovation - St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
| | - Chun Y. Seow
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Centre for Heart Lung Innovation - St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
23
|
Adhikari AS, Kooiker KB, Sarkar SS, Liu C, Bernstein D, Spudich JA, Ruppel KM. Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin. Cell Rep 2016; 17:2857-2864. [PMID: 27974200 PMCID: PMC11088367 DOI: 10.1016/j.celrep.2016.11.040] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 10/11/2016] [Accepted: 11/11/2016] [Indexed: 01/01/2023] Open
Abstract
Hypertrophic cardiomyopathy (HCM) is a heritable cardiovascular disorder that affects 1 in 500 people. A significant percentage of HCM is attributed to mutations in β-cardiac myosin, the motor protein that powers ventricular contraction. This study reports how two early-onset HCM mutations, D239N and H251N, affect the molecular biomechanics of human β-cardiac myosin. We observed significant increases (20%-90%) in actin gliding velocity, intrinsic force, and ATPase activity in comparison to wild-type myosin. Moreover, for H251N, we found significantly lower binding affinity between the S1 and S2 domains of myosin, suggesting that this mutation may further increase hyper-contractility by releasing active motors. Unlike previous HCM mutations studied at the molecular level using human β-cardiac myosin, early-onset HCM mutations lead to significantly larger changes in the fundamental biomechanical parameters and show clear hyper-contractility.
Collapse
Affiliation(s)
- Arjun S Adhikari
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Kristina B Kooiker
- Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Saswata S Sarkar
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Chao Liu
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Daniel Bernstein
- Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA 94305, USA
| | - James A Spudich
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Kathleen M Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA 94305, USA.
| |
Collapse
|
24
|
Zhou Z, Huang W, Liang J, Szczesna-Cordary D. Molecular and Functional Effects of a Splice Site Mutation in the MYL2 Gene Associated with Cardioskeletal Myopathy and Early Cardiac Death in Infants. Front Physiol 2016; 7:240. [PMID: 27378946 PMCID: PMC4911367 DOI: 10.3389/fphys.2016.00240] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2016] [Accepted: 06/03/2016] [Indexed: 12/26/2022] Open
Abstract
The homozygous appearance of the intronic mutation (IVS6-1) in the MYL2 gene encoding for myosin ventricular/slow-twitch skeletal regulatory light chain (RLC) was recently linked to the development of slow skeletal muscle fiber type I hypotrophy and early cardiac death. The IVS6-1 (c403-1G>C) mutation resulted from a cryptic splice site in MYL2 causing a frameshift and replacement of the last 32 codons by 19 different amino acids in the RLC mutant protein. Infants who were IVS6-1+∕+-positive died between 4 and 6 months of age due to cardiomyopathy and heart failure. In this report we have investigated the molecular mechanism and functional consequences associated with the IVS6-1 mutation using recombinant human cardiac IVS6-1 and wild-type (WT) RLC proteins. Recombinant proteins were reconstituted into RLC-depleted porcine cardiac muscle preparations and subjected to enzymatic and functional assays. IVS6-1-RLC showed decreased binding to the myosin heavy chain (MHC) compared with WT, and IVS6-1-reconstituted myosin displayed reduced binding to actin in rigor. The IVS6-1 myosin demonstrated a significantly lower Vmax of the actin-activated myosin ATPase activity compared with WT. In stopped-flow experiments, IVS6-1 myosin showed slower kinetics of the ATP induced dissociation of the acto-myosin complex and a significantly reduced slope of the kobs-[MgATP] relationship compared to WT. In skinned porcine cardiac muscles, RLC-depleted and IVS6-1 reconstituted muscle strips displayed a significant decrease in maximal contractile force and a significantly increased Ca2+ sensitivity, both hallmarks of hypertrophic cardiomyopathy-associated mutations in MYL2. Our results showed that the amino-acid changes in IVS6-1 were sufficient to impose significant conformational alterations in the RLC protein and trigger a series of abnormal protein-protein interactions in the cardiac muscle sarcomere. Notably, the mutation disrupted the RLC-MHC interaction and the steady-state and kinetics of the acto-myosin interaction. Specifically, slower myosin cross-bridge turnover rates and slower second-order MgATP binding rates of acto-myosin interactions were observed in IVS6-1 vs. WT reconstituted cardiac preparations. Our in vitro results suggest that when placed in vivo, IVS6-1 may lead to cardiomyopathy and early death of homozygous infants by severely compromising the ability of myosin to develop contractile force and maintain normal systolic and diastolic cardiac function.
Collapse
Affiliation(s)
- Zhiqun Zhou
- Department of Molecular and Cellular Pharmacology, University of Miami Leonard M. Miller School of Medicine Miami, FL, USA
| | - Wenrui Huang
- Department of Molecular and Cellular Pharmacology, University of Miami Leonard M. Miller School of Medicine Miami, FL, USA
| | - Jingsheng Liang
- Department of Molecular and Cellular Pharmacology, University of Miami Leonard M. Miller School of Medicine Miami, FL, USA
| | - Danuta Szczesna-Cordary
- Department of Molecular and Cellular Pharmacology, University of Miami Leonard M. Miller School of Medicine Miami, FL, USA
| |
Collapse
|
25
|
Nag S, Sommese RF, Ujfalusi Z, Combs A, Langer S, Sutton S, Leinwand LA, Geeves MA, Ruppel KM, Spudich JA. Contractility parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. SCIENCE ADVANCES 2015; 1:e1500511. [PMID: 26601291 PMCID: PMC4646805 DOI: 10.1126/sciadv.1500511] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Accepted: 08/17/2015] [Indexed: 05/20/2023]
Abstract
Hypertrophic cardiomyopathy (HCM) is the most frequently occurring inherited cardiovascular disease. It is caused by mutations in genes encoding the force-generating machinery of the cardiac sarcomere, including human β-cardiac myosin. We present a detailed characterization of the most debated HCM-causing mutation in human β-cardiac myosin, R403Q. Despite numerous studies, most performed with nonhuman or noncardiac myosin, there is no consensus about the mechanism of action of this mutation on the function of the enzyme. We use recombinant human β-cardiac myosin and new methodologies to characterize in vitro contractility parameters of the R403Q myosin compared to wild type. We extend our studies beyond pure actin filaments to include the interaction of myosin with regulated actin filaments containing tropomyosin and troponin. We find that, with pure actin, the intrinsic force generated by R403Q is ~15% lower than that generated by wild type. The unloaded velocity is, however, ~10% higher for R403Q myosin, resulting in a load-dependent velocity curve that has the characteristics of lower contractility at higher external loads compared to wild type. With regulated actin filaments, there is no increase in the unloaded velocity and the contractility of the R403Q myosin is lower than that of wild type at all loads. Unlike that with pure actin, the actin-activated adenosine triphosphatase activity for R403Q myosin with Ca(2+)-regulated actin filaments is ~30% lower than that for wild type, predicting a lower unloaded duty ratio of the motor. Overall, the contractility parameters studied fit with a loss of human β-cardiac myosin contractility as a result of the R403Q mutation.
Collapse
Affiliation(s)
- Suman Nag
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Ruth F. Sommese
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Zoltan Ujfalusi
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK
| | - Ariana Combs
- Department of Molecular, Cellular and Developmental Biology, BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA
| | - Stephen Langer
- Department of Molecular, Cellular and Developmental Biology, BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA
| | - Shirley Sutton
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Leslie A. Leinwand
- Department of Molecular, Cellular and Developmental Biology, BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA
| | | | - Kathleen M. Ruppel
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA 94305, USA
| | - James A. Spudich
- Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
| |
Collapse
|
26
|
Vascular disease-causing mutation R258C in ACTA2 disrupts actin dynamics and interaction with myosin. Proc Natl Acad Sci U S A 2015; 112:E4168-77. [PMID: 26153420 DOI: 10.1073/pnas.1507587112] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Point mutations in vascular smooth muscle α-actin (SM α-actin), encoded by the gene ACTA2, are the most prevalent cause of familial thoracic aortic aneurysms and dissections (TAAD). Here, we provide the first molecular characterization, to our knowledge, of the effect of the R258C mutation in SM α-actin, expressed with the baculovirus system. Smooth muscles are unique in that force generation requires both interaction of stable actin filaments with myosin and polymerization of actin in the subcortical region. Both aspects of R258C function therefore need investigation. Total internal reflection fluorescence (TIRF) microscopy was used to quantify the growth of single actin filaments as a function of time. R258C filaments are less stable than WT and more susceptible to severing by cofilin. Smooth muscle tropomyosin offers little protection from cofilin cleavage, unlike its effect on WT actin. Unexpectedly, profilin binds tighter to the R258C monomer, which will increase the pool of globular actin (G-actin). In an in vitro motility assay, smooth muscle myosin moves R258C filaments more slowly than WT, and the slowing is exacerbated by smooth muscle tropomyosin. Under loaded conditions, small ensembles of myosin are unable to produce force on R258C actin-tropomyosin filaments, suggesting that tropomyosin occupies an inhibitory position on actin. Many of the observed defects cannot be explained by a direct interaction with the mutated residue, and thus the mutation allosterically affects multiple regions of the monomer. Our results align with the hypothesis that defective contractile function contributes to the pathogenesis of TAAD.
Collapse
|
27
|
Gupte TM, Haque F, Gangadharan B, Sunitha MS, Mukherjee S, Anandhan S, Rani DS, Mukundan N, Jambekar A, Thangaraj K, Sowdhamini R, Sommese RF, Nag S, Spudich JA, Mercer JA. Mechanistic heterogeneity in contractile properties of α-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies. J Biol Chem 2014; 290:7003-15. [PMID: 25548289 DOI: 10.1074/jbc.m114.596676] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The most frequent known causes of primary cardiomyopathies are mutations in the genes encoding sarcomeric proteins. Among those are 30 single-residue mutations in TPM1, the gene encoding α-tropomyosin. We examined seven mutant tropomyosins, E62Q, D84N, I172T, L185R, S215L, D230N, and M281T, that were chosen based on their clinical severity and locations along the molecule. The goal of our study was to determine how the biochemical characteristics of each of these mutant proteins are altered, which in turn could provide a structural rationale for treatment of the cardiomyopathies they produce. Measurements of Ca(2+) sensitivity of human β-cardiac myosin ATPase activity are consistent with the hypothesis that hypertrophic cardiomyopathies are hypersensitive to Ca(2+) activation, and dilated cardiomyopathies are hyposensitive. We also report correlations between ATPase activity at maximum Ca(2+) concentrations and conformational changes in TnC measured using a fluorescent probe, which provide evidence that different substitutions perturb the structure of the regulatory complex in different ways. Moreover, we observed changes in protein stability and protein-protein interactions in these mutants. Our results suggest multiple mechanistic pathways to hypertrophic and dilated cardiomyopathies. Finally, we examined a computationally designed mutant, E181K, that is hypersensitive, confirming predictions derived from in silico structural analysis.
Collapse
Affiliation(s)
- Tejas M Gupte
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India
| | - Farah Haque
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India, the National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore 560065, India
| | - Binnu Gangadharan
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India, the Manipal University, Madhav Nagar, Manipal 576104, India
| | - Margaret S Sunitha
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India, the National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore 560065, India
| | - Souhrid Mukherjee
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India
| | - Swetha Anandhan
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India
| | - Deepa Selvi Rani
- the Council for Scientific and Industrial Research-Centre for Cellular and Molecular Biology, Hyderabad 500007, India
| | - Namita Mukundan
- the National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore 560065, India
| | - Amruta Jambekar
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India
| | - Kumarasamy Thangaraj
- the Council for Scientific and Industrial Research-Centre for Cellular and Molecular Biology, Hyderabad 500007, India
| | - Ramanathan Sowdhamini
- the National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore 560065, India
| | - Ruth F Sommese
- the Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, and
| | - Suman Nag
- the Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, and
| | - James A Spudich
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India, the Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, and
| | - John A Mercer
- From the Institute for Stem Cell Biology and Regenerative Medicine, Bangalore 560065, India, the McLaughlin Research Institute, Great Falls, Montana 59405
| |
Collapse
|
28
|
Bookwalter CS, Kelsen A, Leung JM, Ward GE, Trybus KM. A Toxoplasma gondii class XIV myosin, expressed in Sf9 cells with a parasite co-chaperone, requires two light chains for fast motility. J Biol Chem 2014; 289:30832-30841. [PMID: 25231988 DOI: 10.1074/jbc.m114.572453] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Many diverse myosin classes can be expressed using the baculovirus/Sf9 insect cell expression system, whereas others have been recalcitrant. We hypothesized that most myosins utilize Sf9 cell chaperones, but others require an organism-specific co-chaperone. TgMyoA, a class XIVa myosin from the parasite Toxoplasma gondii, is required for the parasite to efficiently move and invade host cells. The T. gondii genome contains one UCS family myosin co-chaperone (TgUNC). TgMyoA expressed in Sf9 cells was soluble and functional only if the heavy and light chain(s) were co-expressed with TgUNC. The tetratricopeptide repeat domain of TgUNC was not essential to obtain functional myosin, implying that there are other mechanisms to recruit Hsp90. Purified TgMyoA heavy chain complexed with its regulatory light chain (TgMLC1) moved actin in a motility assay at a speed of ∼1.5 μm/s. When a putative essential light chain (TgELC1) was also bound, TgMyoA moved actin at more than twice that speed (∼3.4 μm/s). This result implies that two light chains bind to and stabilize the lever arm, the domain that amplifies small motions at the active site into the larger motions that propel actin at fast speeds. Our results show that the TgMyoA domain structure is more similar to other myosins than previously appreciated and provide a molecular explanation for how it moves actin at fast speeds. The ability to express milligram quantities of a class XIV myosin in a heterologous system paves the way for detailed structure-function analysis of TgMyoA and identification of small molecule inhibitors.
Collapse
Affiliation(s)
- Carol S Bookwalter
- Departments of Molecular Physiology and Biophysics and University of Vermont, Burlington, Vermont 05405
| | - Anne Kelsen
- Departments of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont 05405
| | - Jacqueline M Leung
- Departments of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont 05405
| | - Gary E Ward
- Departments of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont 05405.
| | - Kathleen M Trybus
- Departments of Molecular Physiology and Biophysics and University of Vermont, Burlington, Vermont 05405.
| |
Collapse
|
29
|
Muthu P, Liang J, Schmidt W, Moore JR, Szczesna-Cordary D. In vitro rescue study of a malignant familial hypertrophic cardiomyopathy phenotype by pseudo-phosphorylation of myosin regulatory light chain. Arch Biochem Biophys 2014; 552-553:29-39. [PMID: 24374283 PMCID: PMC4043912 DOI: 10.1016/j.abb.2013.12.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Revised: 12/02/2013] [Accepted: 12/16/2013] [Indexed: 11/18/2022]
Abstract
Pseudo-phosphorylation of cardiac myosin regulatory light chain (RLC) has never been examined as a rescue method to alleviate a cardiomyopathy phenotype brought about by a disease causing mutation in the myosin RLC. This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC). The mutation has also been demonstrated to cause severe functional abnormalities in transgenic mice expressing D166V in the heart. To explore this novel rescue strategy, pseudo-phosphorylation of D166V was used to determine whether the D166V-induced detrimental phenotype could be brought back to the level of wild-type (WT) RLC. The S15D substitution at the phosphorylation site of RLC was inserted into the recombinant WT and D166V mutant to mimic constitutively phosphorylated RLC proteins. Non-phosphorylatable (S15A) constructs were used as controls. A multi-faceted approach was taken to determine the effect of pseudo-phosphorylation on the ability of myosin to generate force and motion. Using mutant reconstituted porcine cardiac muscle preparations, we showed an S15D-induced rescue of both the enzymatic and binding properties of D166V-myosin to actin. A significant increase in force production capacity was noted in the in vitro motility assays for S15D-D166V vs. D166V reconstituted myosin. A similar pseudo-phosphorylation induced effect was observed on the D166V-elicited abnormal Ca(2+) sensitivity of force in porcine papillary muscle strips reconstituted with phosphomimic recombinant RLCs. Results from this study demonstrate a novel in vitro rescue strategy that could be utilized in vivo to ameliorate a malignant cardiomyopathic phenotype. We show for the first time that pseudo-RLC phosphorylation can reverse the majority of the mutation-induced phenotypes highlighting the importance of RLC phosphorylation in combating cardiac disease.
Collapse
Affiliation(s)
- Priya Muthu
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
| | - Jingsheng Liang
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
| | - William Schmidt
- Department of Physiology and Biophysics, Boston University School of Medicine, Boston, MA 02118, USA
| | - Jeffrey R Moore
- Department of Physiology and Biophysics, Boston University School of Medicine, Boston, MA 02118, USA
| | - Danuta Szczesna-Cordary
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
| |
Collapse
|
30
|
Jackson DR, Webb M, Stewart TJ, Phillips T, Carter M, Cremo CR, Baker JE. Sucrose increases the activation energy barrier for actin-myosin strong binding. Arch Biochem Biophys 2014; 552-553:74-82. [PMID: 24370736 PMCID: PMC4043939 DOI: 10.1016/j.abb.2013.12.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 12/02/2013] [Accepted: 12/17/2013] [Indexed: 11/21/2022]
Abstract
To determine the mechanism by which sucrose slows in vitro actin sliding velocities, V, we used stopped flow kinetics and a single molecule binding assay, SiMBA. We observed that in the absence of ATP, sucrose (880mM) slowed the rate of actin-myosin (A-M) strong binding by 71±8% with a smaller inhibitory effect observed on spontaneous rigor dissociation (21±3%). Similarly, in the presence of ATP, sucrose slowed strong binding associated with Pi release by 85±9% with a smaller inhibitory effect on ATP-induced A-M dissociation, kT (39±2%). Sucrose had no noticeable effect on any other step in the ATPase reaction. In SiMBA, sucrose had a relatively small effect on the diffusion coefficient for actin fragments (25±2%), and with stopped flow we showed that sucrose increased the activation energy barrier for A-M strong binding by 37±3%, indicating that sucrose inhibits the rate of A-M strong binding by slowing bond formation more than diffusional searching. The inhibitory effects of sucrose on the rate of A-M rigor binding (71%) are comparable in magnitude to sucrose's effects on both V (79±33% decrease) and maximal actin-activated ATPase, kcat, (81±16% decrease), indicating that the rate of A-M strong bond formation significantly influences both kcat and V.
Collapse
Affiliation(s)
- Del R Jackson
- Department of Biomedical Engineering, University of Nevada, Reno, NV, United States
| | - Milad Webb
- Department of Biomedical Engineering, University of Nevada, Reno, NV, United States
| | - Travis J Stewart
- Department of Biochemistry and Molecular Biology, University of Nevada School of Medicine, Reno, NV, United States
| | - Travis Phillips
- Department of Biochemistry and Molecular Biology, University of Nevada School of Medicine, Reno, NV, United States
| | - Michael Carter
- Department of Pharmacology, University of Nevada School of Medicine, Reno, NV, United States
| | - Christine R Cremo
- Department of Biochemistry and Molecular Biology, University of Nevada School of Medicine, Reno, NV, United States
| | - Josh E Baker
- Department of Biochemistry and Molecular Biology, University of Nevada School of Medicine, Reno, NV, United States.
| |
Collapse
|
31
|
Role of the essential light chain in the activation of smooth muscle myosin by regulatory light chain phosphorylation. J Struct Biol 2013; 185:375-82. [PMID: 24361582 DOI: 10.1016/j.jsb.2013.12.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 12/15/2013] [Accepted: 12/16/2013] [Indexed: 11/21/2022]
Abstract
The activity of smooth and non-muscle myosin II is regulated by phosphorylation of the regulatory light chain (RLC) at serine 19. The dephosphorylated state of full-length monomeric myosin is characterized by an asymmetric intramolecular head-head interaction that completely inhibits the ATPase activity, accompanied by a hairpin fold of the tail, which prevents filament assembly. Phosphorylation of serine 19 disrupts these head-head interactions by an unknown mechanism. Computational modeling (Tama et al., 2005. J. Mol. Biol. 345, 837-854) suggested that formation of the inhibited state is characterized by both torsional and bending motions about the myosin heavy chain (HC) at a location between the RLC and the essential light chain (ELC). Therefore, altering relative motions between the ELC and the RLC at this locus might disrupt the inhibited state. Based on this hypothesis we have derived an atomic model for the phosphorylated state of the smooth muscle myosin light chain domain (LCD). This model predicts a set of specific interactions between the N-terminal residues of the RLC with both the myosin HC and the ELC. Site directed mutagenesis was used to show that interactions between the phosphorylated N-terminus of the RLC and helix-A of the ELC are required for phosphorylation to activate smooth muscle myosin.
Collapse
|
32
|
Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function. Proc Natl Acad Sci U S A 2013; 110:12607-12. [PMID: 23798412 DOI: 10.1073/pnas.1309493110] [Citation(s) in RCA: 136] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Cardiovascular disorders are the leading cause of morbidity and mortality in the developed world, and hypertrophic cardiomyopathy (HCM) is among the most frequently occurring inherited cardiac disorders. HCM is caused by mutations in the genes encoding the fundamental force-generating machinery of the cardiac muscle, including β-cardiac myosin. Here, we present a biomechanical analysis of the HCM-causing mutation, R453C, in the context of human β-cardiac myosin. We found that this mutation causes a ∼30% decrease in the maximum ATPase of the human β-cardiac subfragment 1, the motor domain of myosin, and a similar percent decrease in the in vitro velocity. The major change in the R453C human β-cardiac subfragment 1 is a 50% increase in the intrinsic force of the motor compared with wild type, with no appreciable change in the stroke size, as observed with a dual-beam optical trap. These results predict that the overall force of the ensemble of myosin molecules in the muscle should be higher in the R453C mutant compared with wild type. Loaded in vitro motility assay confirms that the net force in the ensemble is indeed increased. Overall, this study suggests that the R453C mutation should result in a hypercontractile state in the heart muscle.
Collapse
|
33
|
Kazmierczak K, Paulino EC, Huang W, Muthu P, Liang J, Yuan CC, Rojas AI, Hare JM, Szczesna-Cordary D. Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2013; 305:H575-89. [PMID: 23748425 DOI: 10.1152/ajpheart.00107.2013] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The functional consequences of the familial hypertrophic cardiomyopathy A57G (alanine-to-glycine) mutation in the myosin ventricular essential light chain (ELC) were assessed in vitro and in vivo using previously generated transgenic (Tg) mice expressing A57G-ELC mutant vs. wild-type (WT) of human cardiac ELC and in recombinant A57G- or WT-protein-exchanged porcine cardiac muscle strips. Compared with the Tg-WT, there was a significant increase in the Ca²⁺ sensitivity of force (ΔpCa₅₀ ≅ 0.1) and an ~1.3-fold decrease in maximal force per cross section of muscle observed in the mutant preparations. In addition, a significant increase in passive tension in response to stretch was monitored in Tg-A57G vs. Tg-WT strips indicating a mutation-induced myocardial stiffness. Consistently, the hearts of Tg-A57G mice demonstrated a high level of fibrosis and hypertrophy manifested by increased heart weight-to-body weight ratios and a decreased number of nuclei indicating an increase in the two-dimensional size of Tg-A57G vs. Tg-WT myocytes. Echocardiography examination showed a phenotype of eccentric hypertrophy in Tg-A57G mice, enhanced left ventricular (LV) cavity dimension without changes in LV posterior/anterior wall thickness. Invasive hemodynamics data revealed significantly increased end-systolic elastance, defined by the slope of the pressure-volume relationship, indicating a mutation-induced increase in cardiac contractility. Our results suggest that the A57G allele causes disease by means of a discrete modulation of myofilament function, increased Ca²⁺ sensitivity, and decreased maximal tension followed by compensatory hypertrophy and enhanced contractility. These and other contributing factors such as increased myocardial stiffness and fibrosis most likely activate cardiomyopathic signaling pathways leading to pathologic cardiac remodeling.
Collapse
Affiliation(s)
- Katarzyna Kazmierczak
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida; and
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Wang Y, Ajtai K, Burghardt TP. The Qdot-labeled actin super-resolution motility assay measures low-duty cycle muscle myosin step size. Biochemistry 2013; 52:1611-21. [PMID: 23383646 DOI: 10.1021/bi301702p] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Myosin powers contraction in heart and skeletal muscle and is a leading target for mutations implicated in inheritable muscle diseases. During contraction, myosin transduces ATP free energy into the work of muscle shortening against resisting force. Muscle shortening involves relative sliding of myosin and actin filaments. Skeletal actin filaments were fluorescently labeled with a streptavidin conjugate quantum dot (Qdot) binding biotin-phalloidin on actin. Single Qdots were imaged in time with total internal reflection fluorescence microscopy and then spatially localized to 1-3 nm using a super-resolution algorithm as they translated with actin over a surface coated with skeletal heavy meromyosin (sHMM) or full-length β-cardiac myosin (MYH7). The average Qdot-actin velocity matches measurements with rhodamine-phalloidin-labeled actin. The sHMM Qdot-actin velocity histogram contains low-velocity events corresponding to actin translation in quantized steps of ~5 nm. The MYH7 velocity histogram has quantized steps at 3 and 8 nm in addition to 5 nm and larger compliance compared to that of sHMM depending on the MYH7 surface concentration. Low-duty cycle skeletal and cardiac myosin present challenges for a single-molecule assay because actomyosin dissociates quickly and the freely moving element diffuses away. The in vitro motility assay has modestly more actomyosin interactions, and methylcellulose inhibited diffusion to sustain the complex while preserving a subset of encounters that do not overlap in time on a single actin filament. A single myosin step is isolated in time and space and then characterized using super-resolution. The approach provides a quick, quantitative, and inexpensive step size measurement for low-duty cycle muscle myosin.
Collapse
Affiliation(s)
- Yihua Wang
- Department of Biochemistry and Molecular Biology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
| | | | | |
Collapse
|
35
|
Kazmierczak K, Muthu P, Huang W, Jones M, Wang Y, Szczesna-Cordary D. Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice. Biochem J 2012; 442:95-103. [PMID: 22091967 PMCID: PMC6589164 DOI: 10.1042/bj20111145] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
FHC (familial hypertrophic cardiomyopathy) is a heritable form of cardiac hypertrophy caused by mutations in genes encoding sarcomeric proteins. The present study focuses on the A13T mutation in the human ventricular myosin RLC (regulatory light chain) that is associated with a rare FHC variant defined by mid-ventricular obstruction and septal hypertrophy. We generated heart-specific Tg (transgenic) mice with ~10% of human A13T-RLC mutant replacing the endogenous mouse cardiac RLC. Histopathological examinations of longitudinal heart sections from Tg-A13T mice showed enlarged interventricular septa and profound fibrotic lesions compared with Tg-WT (wild-type), expressing the human ventricular RLC, or non-Tg mice. Functional studies revealed an abnormal A13T mutation-induced increase in isometric force production, no change in the force-pCa relationship and a decreased Vmax of the acto-myosin ATPase. In addition, a fluorescence-based assay showed a 3-fold lower binding affinity of the recombinant A13T mutant for the RLC-depleted porcine myosin compared with WT-RLC. These results suggest that the A13T mutation triggers a hypertrophic response through changes in cardiac sarcomere organization and myosin cross-bridge function leading to abnormal remodelling of the heart. The significant functional changes observed, despite a low level of A13T mutant incorporation into myofilaments, suggest a 'poison-peptide' mechanism of disease.
Collapse
Affiliation(s)
- Katarzyna Kazmierczak
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A
| | - Priya Muthu
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A
| | - Wenrui Huang
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A
| | - Michelle Jones
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A
| | - Yingcai Wang
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A
| | - Danuta Szczesna-Cordary
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A
| |
Collapse
|
36
|
Goguen BN, Hoffman BD, Sellers JR, Schwartz MA, Imperiali B. Light-Triggered Myosin Activation for Probing Dynamic Cellular Processes. Angew Chem Int Ed Engl 2011. [DOI: 10.1002/ange.201100674] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
37
|
Goguen BN, Hoffman BD, Sellers JR, Schwartz MA, Imperiali B. Light-triggered myosin activation for probing dynamic cellular processes. Angew Chem Int Ed Engl 2011; 50:5667-70. [PMID: 21542072 DOI: 10.1002/anie.201100674] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2011] [Indexed: 11/05/2022]
Affiliation(s)
- Brenda N Goguen
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | | | | | | |
Collapse
|
38
|
Zhang Y, Nakamura A, Kawamichi H, Yoshiyama S, Katayama T, Kohama K. Calcium regulation of the ATPase activity of Physarum
and scallop myosins using hybrid smooth muscle myosin: The role of the essential light chain. FEBS Lett 2010; 584:3486-91. [DOI: 10.1016/j.febslet.2010.07.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2010] [Revised: 07/06/2010] [Accepted: 07/06/2010] [Indexed: 10/19/2022]
|
39
|
Functional diversity among a family of human skeletal muscle myosin motors. Proc Natl Acad Sci U S A 2009; 107:1053-8. [PMID: 20080549 DOI: 10.1073/pnas.0913527107] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Human skeletal muscle fibers express five highly conserved type-II myosin heavy chain (MyHC) genes in distinct spatial and temporal patterns. In addition, the human genome contains an intact sixth gene, MyHC-IIb, which is thought under most circumstances not to be expressed. The physiological and biochemical properties of individual muscle fibers correlate with the predominantly expressed MyHC isoform, but a functional analysis of homogenous skeletal muscle myosin isoforms has not been possible. This is due to the difficulties of separating the multiple isoforms usually coexpressed in muscle fibers, as well as the lack of an expression system that produces active recombinant type II skeletal muscle myosin. In this study we describe a mammalian muscle cell expression system and the functional analysis of all six recombinant human type II skeletal muscle myosin isoforms. The diverse biochemical activities and actin-filament velocities of these myosins indicate that they likely have distinct functions in muscle. Our data also show that ATPase activity and motility are generally correlated for human skeletal muscle myosins. The exception, MyHC-IIb, encodes a protein that is high in ATPase activity but slow in motility; this is the first functional analysis of the protein from this gene. In addition, the developmental isoforms, hypothesized to have low ATPase activity, were indistinguishable from adult-fast MyHC-IIa and the specialized MyHC-Extraocular isoform, that was predicted to be the fastest of all six isoforms but was functionally similar to the slower isoforms.
Collapse
|
40
|
Isolation and Fluorescence Spectrum of Cardiac Myosin from Pig Heart. Protein J 2009; 28:169-74. [DOI: 10.1007/s10930-009-9180-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Kazmierczak K, Xu Y, Jones M, Guzman G, Hernandez OM, Kerrick WGL, Szczesna-Cordary D. The role of the N-terminus of the myosin essential light chain in cardiac muscle contraction. J Mol Biol 2009; 387:706-25. [PMID: 19361417 DOI: 10.1016/j.jmb.2009.02.006] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2008] [Revised: 02/02/2009] [Accepted: 02/05/2009] [Indexed: 10/21/2022]
Abstract
To study the regulation of cardiac muscle contraction by the myosin essential light chain (ELC) and the physiological significance of its N-terminal extension, we generated transgenic (Tg) mice by partially replacing the endogenous mouse ventricular ELC with either the human ventricular ELC wild type (Tg-WT) or its 43-amino-acid N-terminal truncation mutant (Tg-Delta43) in the murine hearts. The mutant protein is similar in sequence to the short ELC variant present in skeletal muscle, and the ELC protein distribution in Tg-Delta43 ventricles resembles that of fast skeletal muscle. Cardiac muscle preparations from Tg-Delta43 mice demonstrate reduced force per cross-sectional area of muscle, which is likely caused by a reduced number of force-generating myosin cross-bridges and/or by decreased force per cross-bridge. As the mice grow older, the contractile force per cross-sectional area further decreases in Tg-Delta43 mice and the mutant hearts develop a phenotype of nonpathologic hypertrophy while still maintaining normal cardiac performance. The myocardium of older Tg-Delta43 mice also exhibits reduced myosin content. Our results suggest that the role of the N-terminal ELC extension is to maintain the integrity of myosin and to modulate force generation by decreasing myosin neck region compliance and promoting strong cross-bridge formation and/or by enhancing myosin attachment to actin.
Collapse
Affiliation(s)
- Katarzyna Kazmierczak
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Léguillette R, Zitouni NB, Govindaraju K, Fong LM, Lauzon AM. Affinity for MgADP and force of unbinding from actin of myosin purified from tonic and phasic smooth muscle. Am J Physiol Cell Physiol 2008; 295:C653-60. [PMID: 18614813 DOI: 10.1152/ajpcell.00100.2008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Smooth muscle is unique in its ability to maintain force at low MgATP consumption. This property, called the latch state, is more prominent in tonic than phasic smooth muscle. Studies performed at the muscle strip level have suggested that myosin from tonic muscle has a greater affinity for MgADP and therefore remains attached to actin longer than myosin from phasic muscle, allowing for cross-bridge dephosphorylation and latch-bridge formation. An alternative hypothesis is that after dephosphorylation, myosin reattaches to actin and maintains force. We investigated these fundamental properties of smooth muscle at the molecular level. We used an in vitro motility assay to measure actin filament velocity (nu(max)) when propelled by myosin purified from phasic or tonic muscle at increasing [MgADP]. Myosin was 25% thiophosphorylated and 75% unphosphorylated to approximate in vivo conditions. The slope of nu(max) versus [MgADP] was significantly greater for tonic (-0.51+/-0.04) than phasic muscle myosin (-0.15+/-0.04), demonstrating the greater MgADP affinity of myosin from tonic muscle. We then used a laser trap assay to measure the unbinding force from actin of populations of unphosphorylated tonic and phasic muscle myosin. Both myosin types attached to actin, and their unbinding force (0.092+/-0.022 pN for phasic muscle and 0.084+/-0.017 pN for tonic muscle) was not statistically different. We conclude that the greater affinity for MgADP of tonic muscle myosin and the reattachment of dephosphorylated myosin to actin may both contribute to the latch state.
Collapse
Affiliation(s)
- Renaud Léguillette
- Meakins-Christie Laboratories, Department of Medicine, McGill University, 3626 St-Urbain St., Montreal, QC, Canada H2X 2P2
| | | | | | | | | |
Collapse
|
43
|
Lowey S, Lesko LM, Rovner AS, Hodges AR, White SL, Low RB, Rincon M, Gulick J, Robbins J. Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone. J Biol Chem 2008; 283:20579-89. [PMID: 18480046 DOI: 10.1074/jbc.m800554200] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The R403Q mutation in the beta-myosin heavy chain (MHC) was the first mutation to be linked to familial hypertrophic cardiomyopathy (FHC), a primary disease of heart muscle. The initial studies with R403Q myosin, isolated from biopsies of patients, showed a large decrease in myosin motor function, leading to the hypothesis that hypertrophy was a compensatory response. The introduction of the mouse model for FHC (the mouse expresses predominantly alpha-MHC as opposed to the beta-isoform in larger mammals) created a new paradigm for FHC based on finding enhanced motor function for R403Q alpha-MHC. To help resolve these conflicting mechanisms, we used a transgenic mouse model in which the endogenous alpha-MHC was largely replaced with transgenically encoded beta-MHC. A His(6) tag was cloned at the N terminus of the alpha-and beta-MHC to facilitate protein isolation by Ni(2+)-chelating chromatography. Characterization of the R403Q alpha-MHC by the in vitro motility assay showed a 30-40% increase in actin filament velocity compared with wild type, consistent with published studies. In contrast, the R403Q mutation in a beta-MHC backbone showed no enhancement in velocity. Cleavage of the His-tagged myosin by chymotrypsin made it possible to isolate homogeneous myosin subfragment 1 (S1), uncontaminated by endogenous myosin. We find that the actin-activated MgATPase activity for R403Q alpha-S1 is approximately 30% higher than for wild type, whereas the enzymatic activity for R403Q beta-S1 is reduced by approximately 10%. Thus, the functional consequences of the mutation are fundamentally changed depending upon the context of the cardiac MHC isoform.
Collapse
Affiliation(s)
- Susan Lowey
- Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, VT 05405, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Miller BM, Trybus KM. Functional effects of nemaline myopathy mutations on human skeletal alpha-actin. J Biol Chem 2008; 283:19379-88. [PMID: 18477565 DOI: 10.1074/jbc.m801963200] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Mutations in human alpha-skeletal actin have been implicated in causing congenital nemaline myopathy, a disease characterized histopathologically by nemaline bodies in skeletal muscle and manifested in the patient as skeletal muscle weakness. Here we investigate the functional effects of three severe nemaline myopathy mutations (V43F, A138P, and R183G) in human alpha-skeletal actin. Wild-type and mutant actins were expressed and purified from the baculovirus/insect cell expression system. The mutations are located in different subdomains of actin; Val-43 is located in a flexible loop of subdomain 2, Ala-138 is near a hydrophobic cleft in the "hinge" region between subdomains 1 and 3, and Arg-183 is near the nucleotide-binding site. None of the three mutations affected the folding of the actin monomer, the velocity at which skeletal myosin moves actin in an in vitro motility assay, or the relative average isometric force supported by F-actin. Defects in fundamental actomyosin interactions are, therefore, unlikely to account for the muscle weakness observed in affected patients. There were, however, significant changes observed in the polymerization kinetics of V43F and A138P and in the rate of nucleotide release for V43F. No detectable defect was found for R183G. If these subtle changes in polymerization observed in vitro are amplified in the context of the sarcomere, it could in principle be one of the primary insults that triggers the development of nemaline myopathy.
Collapse
Affiliation(s)
- Becky M Miller
- Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont 05405, USA
| | | |
Collapse
|
45
|
Matsson H, Eason J, Bookwalter CS, Klar J, Gustavsson P, Sunnegårdh J, Enell H, Jonzon A, Vikkula M, Gutierrez I, Granados-Riveron J, Pope M, Bu’Lock F, Cox J, Robinson TE, Song F, Brook DJ, Marston S, Trybus KM, Dahl N. Alpha-cardiac actin mutations produce atrial septal defects. Hum Mol Genet 2007; 17:256-65. [DOI: 10.1093/hmg/ddm302] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Lowey S, Saraswat LD, Liu H, Volkmann N, Hanein D. Evidence for an interaction between the SH3 domain and the N-terminal extension of the essential light chain in class II myosins. J Mol Biol 2007; 371:902-13. [PMID: 17597155 PMCID: PMC2693010 DOI: 10.1016/j.jmb.2007.05.080] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2007] [Revised: 05/23/2007] [Accepted: 05/24/2007] [Indexed: 10/23/2022]
Abstract
The function of the src-homology 3 (SH3) domain in class II myosins, a distinct beta-barrel structure, remains unknown. Here, we provide evidence, using electron cryomicroscopy, in conjunction with light-scattering, fluorescence and kinetic analyses, that the SH3 domain facilitates the binding of the N-terminal extension of the essential light chain isoform (ELC-1) to actin. The 41 residue extension contains four conserved lysine residues followed by a repeating sequence of seven Pro/Ala residues. It is widely believed that the highly charged region interacts with actin, while the Pro/Ala-rich sequence forms a rigid tether that bridges the approximately 9 nm distance between the myosin lever arm and the thin filament. In order to localize the N terminus of ELC in the actomyosin complex, an engineered Cys was reacted with undecagold-maleimide, and the labeled ELC was exchanged into myosin subfragment-1 (S1). Electron cryomicroscopy of S1-bound actin filaments, together with computer-based docking of the skeletal S1 crystal structure into 3D reconstructions, showed a well-defined peak for the gold cluster near the SH3 domain. Given that SH3 domains are known to bind proline-rich ligands, we suggest that the N-terminal extension of ELC interacts with actin and modulates myosin kinetics by binding to the SH3 domain during the ATPase cycle.
Collapse
Affiliation(s)
- Susan Lowey
- Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, VT 05405, USA
- Correspondence should be addressed to S.L. e-mail: or N.V. e-mail:
| | | | - HongJun Liu
- The Program of Cell Adhesion, Burnham Institute for Medical Research, La Jolla, CA 92037, USA
| | - Niels Volkmann
- The Program of Cell Adhesion, Burnham Institute for Medical Research, La Jolla, CA 92037, USA
- Correspondence should be addressed to S.L. e-mail: or N.V. e-mail:
| | - Dorit Hanein
- The Program of Cell Adhesion, Burnham Institute for Medical Research, La Jolla, CA 92037, USA
| |
Collapse
|
47
|
Kad NM, Patlak JB, Fagnant PM, Trybus KM, Warshaw DM. Mutation of a conserved glycine in the SH1-SH2 helix affects the load-dependent kinetics of myosin. Biophys J 2006; 92:1623-31. [PMID: 17142278 PMCID: PMC1796825 DOI: 10.1529/biophysj.106.097618] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The ATP hydrolysis rate and shortening velocity of muscle are load-dependent. At the molecular level, myosin generates force and motion by coupling ATP hydrolysis to lever arm rotation. When a laser trap was used to apply load to single heads of expressed smooth muscle myosin (S1), the ADP release kinetics accelerated with an assistive load and slowed with a resistive load; however, ATP binding was mostly unaffected. To investigate how load is communicated within the motor, a glycine located at the putative fulcrum of the lever arm was mutated to valine (G709V). In the absence of load, stopped-flow and laser trap studies showed that the mutation significantly slowed the rates of ADP release and ATP binding, accounting for the approximately 270-fold decrease in actin sliding velocity. The load dependence of the mutant's ADP release rate was the same as that of wild-type S1 (WT) despite the slower rate. In contrast, load accelerated ATP binding by approximately 20-fold, irrespective of loading direction. Imparting mechanical energy to the mutant motor partially reversed the slowed ATP binding by overcoming the elevated activation energy barrier. These results imply that conformational changes near the conserved G709 are critical for the transmission of mechanochemical information between myosin's active site and lever arm.
Collapse
Affiliation(s)
- Neil M Kad
- Department of Molecular Physiology & Biophysics, University of Vermont, Burlington, Vermont 05405, USA
| | | | | | | | | |
Collapse
|
48
|
Eddinger TJ, Meer DP, Miner AS, Meehl J, Rovner AS, Ratz PH. Potent inhibition of arterial smooth muscle tonic contractions by the selective myosin II inhibitor, blebbistatin. J Pharmacol Exp Ther 2006; 320:865-70. [PMID: 17132816 DOI: 10.1124/jpet.106.109363] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Blebbistatin is reported to be a selective and specific small molecule inhibitor of the myosin II isoforms expressed by striated muscles and nonmuscle (IC(50) = 0.5-5 microM) but is a poor inhibitor of purified turkey smooth muscle myosin II (IC(50) approximately 80 microM). We found that blebbistatin potently (IC(50) approximately 3 microM) inhibited the actomyosin ATPase activities of expressed "slow" [smooth muscle myosin IIA (SMA)] and "fast" [smooth muscle myosin IIB (SMB)] smooth muscle myosin II heavy-chain isoforms. Blebbistatin also inhibited the KCl-induced tonic contractions produced by rabbit femoral and renal arteries that express primarily SMA and the weaker tonic contraction produced by the saphenous artery that expresses primarily SMB, with an equivalent potency comparable with that identified for nonmuscle myosin IIA (IC(50) approximately 5 microM). In femoral and saphenous arteries, blebbistatin had no effect on unloaded shortening velocity or the tonic increase in myosin light-chain phosphorylation produced by KCl but potently inhibited beta-escin permeabilized artery contracted with calcium at pCa 5, suggesting that cell signaling events upstream from KCl-induced activation of cross-bridges were unaffected by blebbistatin. It is noteworthy that KCl-induced contractions of chicken gizzard were less potently inhibited (IC(50) approximately 20 microM). Adult femoral, renal, and saphenous arteries did not express significant levels of nonmuscle myosin. These data together indicate that blebbistatin is a potent inhibitor of smooth muscle myosin II, supporting the hypothesis that the force-bearing structure responsible for tonic force maintenance in adult mammalian vascular smooth muscle is the cross-bridge formed from the blebbistatin-dependent interaction between actin and smooth muscle myosin II.
Collapse
Affiliation(s)
- Thomas J Eddinger
- Department of Biological Sciences, Marquette University, Milwaukee, Wisconsin, USA
| | | | | | | | | | | |
Collapse
|
49
|
Bookwalter CS, Trybus KM. Functional Consequences of a Mutation in an Expressed Human α-Cardiac Actin at a Site Implicated in Familial Hypertrophic Cardiomyopathy. J Biol Chem 2006; 281:16777-84. [PMID: 16611632 DOI: 10.1074/jbc.m512935200] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Point mutations in human alpha-cardiac actin cause familial hypertrophic cardiomyopathy. Functional characterization of these actin mutants has been limited by the lack of a high level expression system for human cardiac actin. Here, wild-type (WT) human alpha-cardiac actin and a mutant E99K actin have been expressed and purified from the baculovirus/insect cell expression system. Glu-99 in subdomain 1 of actin is thought to interact with a positively charged cluster located in the lower 50-kDa domain of the myosin motor domain. Actin-activated ATPase measurements using the expressed actins and beta-cardiac myosin showed that the mutation increased the K(m) for actin 4-fold (4.7 +/- 0.7 mum for WT versus 19.1 +/- 3.0 mum for the mutant), whereas the V(max) values were similar. The mutation slightly decreased the affinity of actin for S1 in the absence of nucleotide, which can partly be accounted for by a slower rate of association. The in vitro motility for the E99K mutant was consistently lower than WT over a range of ionic strengths, which is likely related to the lower average force supported by the mutant actin. The thermal stability of the E99K was comparable to that of WT-actin, implying no folding defects. The lower density of negative charge in subdomain 1 of actin therefore weakens the actomyosin interaction sufficiently to decrease the force and motion generating capacity of E99K actin, thus providing the primary insult that ultimately leads to the disease phenotype.
Collapse
Affiliation(s)
- Carol S Bookwalter
- Department of Molecular Physiology, University of Vermont, Burlington, VT 05405, USA
| | | |
Collapse
|
50
|
Rovner AS, Fagnant PM, Trybus KM. Phosphorylation of a single head of smooth muscle myosin activates the whole molecule. Biochemistry 2006; 45:5280-9. [PMID: 16618116 PMCID: PMC2505275 DOI: 10.1021/bi060154c] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Regulatory light chain (RLC) phosphorylation activates smooth and non-muscle myosin II, but it has not been established if phosphorylation of one head turns on the whole molecule. Baculovirus expression and affinity chromatography were used to isolate heavy meromyosin (HMM) containing one phosphorylated and one dephosphorylated RLC (1-P HMM). Motility and steady-state ATPase assays indicated that 1-P HMM is nearly as active as HMM with two phosphorylated heads (2-P HMM). Single-turnover experiments further showed that both the dephosphorylated and phosphorylated heads of 1-P HMM can be activated by actin. Singly phosphorylated full-length myosin was also an active species with two cycling heads. Our results suggest that phosphorylation of one RLC abolishes the asymmetric inhibited state formed by dephosphorylated myosin [Liu, J., et al. (2003) J. Mol. Biol. 329, 963-972], allowing activation of both the phosphorylated and dephosphorylated heads. These findings help explain how smooth muscles are able to generate high levels of stress with low phosphorylation levels.
Collapse
Affiliation(s)
- Arthur S Rovner
- Department of Molecular Physiology and Biophysics, Health Sciences Research Facility, University of Vermont, Burlington, Vermont 05405-0068, USA
| | | | | |
Collapse
|